Zhejiang Xinguang Pharmaceutical Co Ltd
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquar… Read more
Zhejiang Xinguang Pharmaceutical Co Ltd (300519) - Net Assets
Latest net assets as of September 2025: CN¥827.95 Million CNY
Based on the latest financial reports, Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has net assets worth CN¥827.95 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥893.41 Million) and total liabilities (CN¥65.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥827.95 Million |
| % of Total Assets | 92.67% |
| Annual Growth Rate | 17.3% |
| 5-Year Change | 0.43% |
| 10-Year Change | 168.48% |
| Growth Volatility | 28.68 |
Zhejiang Xinguang Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Zhejiang Xinguang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥830.53 Million | -1.61% |
| 2023-12-31 | CN¥844.12 Million | -1.72% |
| 2022-12-31 | CN¥858.89 Million | +1.50% |
| 2021-12-31 | CN¥846.22 Million | +2.33% |
| 2020-12-31 | CN¥826.94 Million | +3.41% |
| 2019-12-31 | CN¥799.71 Million | +6.17% |
| 2018-12-31 | CN¥753.26 Million | +6.72% |
| 2017-12-31 | CN¥705.81 Million | +10.20% |
| 2016-12-31 | CN¥640.46 Million | +107.03% |
| 2015-12-31 | CN¥309.35 Million | +24.24% |
| 2014-12-31 | CN¥249.00 Million | +23.29% |
| 2013-12-31 | CN¥201.97 Million | +42.61% |
| 2012-12-31 | CN¥141.62 Million | +35.76% |
| 2011-12-31 | CN¥104.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Xinguang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 399.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥389.01 Million | 46.84% |
| Common Stock | CN¥160.00 Million | 19.26% |
| Other Comprehensive Income | CN¥120.23 Million | 14.48% |
| Other Components | CN¥161.29 Million | 19.42% |
| Total Equity | CN¥830.53 Million | 100.00% |
Zhejiang Xinguang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Xinguang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Playtika Holding Corp
NASDAQ:PLTK
|
$164.18 Million |
|
Tien Phong Securities Corp
VN:ORS
|
$164.20 Million |
|
TASKUS INC. CL.A DL-01
F:6VY
|
$164.24 Million |
|
USANA Health Sciences Inc
NYSE:USNA
|
$164.25 Million |
|
SOLSTAD OFFSHORE NK 1
F:SZL
|
$164.04 Million |
|
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
|
$164.01 Million |
|
Orogen Royalties Inc
PINK:OGNRF
|
$164.01 Million |
|
Smart Eye AB
ST:SEYE
|
$163.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Xinguang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 844,120,768 to 830,531,829, a change of -13,588,939 (-1.6%).
- Net income of 50,389,992 contributed positively to equity growth.
- Dividend payments of 64,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 116,945,749.
- Other factors decreased equity by 116,924,680.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥50.39 Million | +6.07% |
| Dividends Paid | CN¥64.00 Million | -7.71% |
| Other Comprehensive Income | CN¥116.95 Million | +14.08% |
| Other Changes | CN¥-116.92 Million | -14.08% |
| Total Change | CN¥- | -1.61% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Xinguang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.12x to 3.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.86 | CN¥16.35 | x |
| 2012-12-31 | CN¥1.18 | CN¥16.35 | x |
| 2013-12-31 | CN¥1.69 | CN¥16.35 | x |
| 2014-12-31 | CN¥2.07 | CN¥16.35 | x |
| 2015-12-31 | CN¥2.58 | CN¥16.35 | x |
| 2016-12-31 | CN¥4.79 | CN¥16.35 | x |
| 2017-12-31 | CN¥4.39 | CN¥16.35 | x |
| 2018-12-31 | CN¥4.71 | CN¥16.35 | x |
| 2019-12-31 | CN¥5.00 | CN¥16.35 | x |
| 2020-12-31 | CN¥5.17 | CN¥16.35 | x |
| 2021-12-31 | CN¥5.29 | CN¥16.35 | x |
| 2022-12-31 | CN¥5.37 | CN¥16.35 | x |
| 2023-12-31 | CN¥5.25 | CN¥16.35 | x |
| 2024-12-31 | CN¥5.19 | CN¥16.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Xinguang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.83%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.10x
- Recent ROE (6.07%) is below the historical average (22.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 45.80% | 20.41% | 1.05x | 2.14x | CN¥36.62 Million |
| 2012 | 40.13% | 22.75% | 1.15x | 1.54x | CN¥42.68 Million |
| 2013 | 35.88% | 27.05% | 1.09x | 1.22x | CN¥52.27 Million |
| 2014 | 42.43% | 36.17% | 0.96x | 1.22x | CN¥80.75 Million |
| 2015 | 38.40% | 38.14% | 0.86x | 1.17x | CN¥87.85 Million |
| 2016 | 18.57% | 37.73% | 0.45x | 1.09x | CN¥54.91 Million |
| 2017 | 15.04% | 34.15% | 0.40x | 1.10x | CN¥35.58 Million |
| 2018 | 11.68% | 31.85% | 0.34x | 1.09x | CN¥12.67 Million |
| 2019 | 11.74% | 32.24% | 0.34x | 1.08x | CN¥13.93 Million |
| 2020 | 11.97% | 34.96% | 0.32x | 1.08x | CN¥16.28 Million |
| 2021 | 13.50% | 35.62% | 0.34x | 1.10x | CN¥29.66 Million |
| 2022 | 12.67% | 30.96% | 0.37x | 1.12x | CN¥22.93 Million |
| 2023 | 7.62% | 23.80% | 0.29x | 1.10x | CN¥-20.06 Million |
| 2024 | 6.07% | 18.83% | 0.29x | 1.10x | CN¥-32.66 Million |
Industry Comparison
This section compares Zhejiang Xinguang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,061,893,866
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Xinguang Pharmaceutical Co Ltd (300519) | CN¥827.95 Million | 45.80% | 0.08x | $164.05 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $608.50 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $324.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.92 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $525.21 Million | 17.84% | 0.75x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $4.63 Billion | -3.44% | 1.33x | $704.71 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $325.99 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.07 Billion | 2.59% | 1.71x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $3.91 Billion | 12.94% | 0.18x | $777.45 Million |